Conclusion of non-exclusive pharmaceutical discount agreements for tacrolimus under an open-house model, restricted to the dosage form

Summary

The tender concerns non-exclusive pharmaceutical discount agreements for the active substance tacrolimus under an open-house model, limited to the extended-release tablet dosage form. Participation is open to interested pharmaceutical companies that meet and accept the participation conditions. No individual contract negotiations or supply exclusivity will be provided, and no minimum purchase volumes are guaranteed because demand is unknown. Participation documents must be obtained through the German Procurement Portal project room after requesting access. Submissions are made electronically through the portal; the first submission deadline is 6 October 2026, with further deadlines specified in the project documents. The agreements end no later than 31 October 2027. The participation materials and their contents must be kept confidential.